IDEXX LABORATORIES INC /DE — Director's Dealing 2020

May 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2020-05-08

Reporting Person: AYERS JONATHAN W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-08	Common Stock	M	21130	$62	Acquired	831597	Direct
2020-05-08	Common Stock	S	5136	$290.5939	Disposed	826461	Direct
2020-05-08	Common Stock	S	9953	$291.4147	Disposed	816508	Direct
2020-05-08	Common Stock	S	3440	$292.4399	Disposed	813068	Direct
2020-05-08	Common Stock	S	2601	$293.3966	Disposed	810467	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-08	Non-Qualified Stock Option (right-to-buy)	$62	M	21130	Disposed	2024-02-13	Common Stock (21130)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	98000	Indirect

Footnotes

F1: Represents the weighted average price of the shares sold ranging from a low of $290.00 to a high of $290.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average price of the shares sold ranging from a low of $290.00 to a high of $290.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $292.07 to a high of $293.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $293.13 to a high of 294.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Not applicable.